CGRP neutralizing antibody
Sponsors
Eli Lilly
Conditions
Episodic cluster headache
headachechronic cluster headache
headachecluster headache
headache
Phase 3
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Cluster Headache
Active, not recruitingNL-OMON45305
Start: 2017-01-04Target: 18Updated: 2024-02-28
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 with a Long-Term Open-Label Extension in Patients with Chronic Cluster Headache
Active, not recruitingNL-OMON46914
Start: 2017-01-11Target: 7Updated: 2024-02-28
A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (galcanezumab) in Patients with Episodic or Chronic Cluster Headache
Active, not recruitingNL-OMON47489
Start: 2017-09-01Target: 36Updated: 2024-02-28